Scholarlink

Background <p>Breast cancer (BC) diagnostics are undergoing a transformative shift from traditional morphological assessment to a complex multi-omic characterization. While Immunohistochemistry (IHC) remains the clinical bedrock for subtyping, its inherent inability to account for intra-tumoral heterogeneity and the dynamic nature of clonal evolution has necessitated the integration of high-throughput genomic and transcriptomic tools.</p> Main body <p>This review examines the technological evolution from “gold standard” protein-based assays to precision oncology enabled by Next-Generation Sequencing (NGS) and liquid biopsy. We provide a rigorous analysis of multi-gene expression signatures (Oncotype DX, MammaPrint, Prosigna, EndoPredict) and their impact on clinical decision-making. Furthermore, we explore the clinical utility of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection and the identification of acquired resistance mechanisms involving ESR1, PIK3CA, AKT1, PTEN and ERBB2 mutations. We further address the complex bioinformatics challenges, including variant interpretation, the implementation of Unique Molecular Identifiers (UMIs), and the integration of artificial intelligence in analyzing massive multi-omic datasets.</p> Conclusion <p>The integration of IHC with longitudinal genomic profiling is essential for the future of breast cancer management. This multi-modal approach ensures that therapeutic strategies evolve alongside the tumor's molecular landscape. Future clinical trials must focus on MRD-guided interventions to validate the clinical benefit of early genomic detection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The multi-omic transformation of breast cancer diagnostics: a comprehensive narrative of the transition from immunohistochemistry to liquid biopsy and next-generation sequencing

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月6日

查看全文
  • Farnam Gholipour Maralan

摘要

Background

Breast cancer (BC) diagnostics are undergoing a transformative shift from traditional morphological assessment to a complex multi-omic characterization. While Immunohistochemistry (IHC) remains the clinical bedrock for subtyping, its inherent inability to account for intra-tumoral heterogeneity and the dynamic nature of clonal evolution has necessitated the integration of high-throughput genomic and transcriptomic tools.

Main body

This review examines the technological evolution from “gold standard” protein-based assays to precision oncology enabled by Next-Generation Sequencing (NGS) and liquid biopsy. We provide a rigorous analysis of multi-gene expression signatures (Oncotype DX, MammaPrint, Prosigna, EndoPredict) and their impact on clinical decision-making. Furthermore, we explore the clinical utility of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection and the identification of acquired resistance mechanisms involving ESR1, PIK3CA, AKT1, PTEN and ERBB2 mutations. We further address the complex bioinformatics challenges, including variant interpretation, the implementation of Unique Molecular Identifiers (UMIs), and the integration of artificial intelligence in analyzing massive multi-omic datasets.

Conclusion

The integration of IHC with longitudinal genomic profiling is essential for the future of breast cancer management. This multi-modal approach ensures that therapeutic strategies evolve alongside the tumor's molecular landscape. Future clinical trials must focus on MRD-guided interventions to validate the clinical benefit of early genomic detection.